Skip to main content

Gout

Urate Lowering Therapy During Acute Gout

Jan 26, 2021

Acute gout has its well defined protocols, and most state that urate lowering therapy (ULT) should be continued; but does ULT affect outcomes in an acute gout attack?

Read Article
Sign up to attend RheumNow Live--March 20 and 21. CME credits available https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d
Dr. John Cush RheumNow ( View Tweet)
Jan 20, 2021
2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond. https://t.co/QisCpdcLEa https://t.co/pZekUvcomE
Dr. John Cush RheumNow ( View Tweet)
Jan 16, 2021
Download your RheumaKnowledgy Card https://t.co/L7O0UFjEBV https://t.co/iFtVKERnjC
Dr. John Cush RheumNow ( View Tweet)
Jan 12, 2021
ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR

Dr. John Cush RheumNow ( View Tweet)

Jan 11, 2021
Rheumatologists: Record your question or case for the RheumNow podcast. https://t.co/NDhYNX50e2

Dr. John Cush RheumNow ( View Tweet)

Jan 09, 2021
Join us this March for RheumNow Live! Sign up via the link below. https://t.co/vJlU0Z3Q3x https://t.co/G1s3F7zKlI
Dr. John Cush RheumNow ( View Tweet)
Jan 05, 2021
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zJJp8

Dr. John Cush RheumNow ( View Tweet)

Jan 05, 2021
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zs8xA

Dr. John Cush RheumNow ( View Tweet)

Jan 03, 2021
Five Gout Studies Reviewed: Dr. Bella Mehta #ACR20 https://t.co/xTaw4HkD0c https://t.co/904zaAUm1o
Dr. John Cush RheumNow ( View Tweet)
Dec 29, 2020
Content Download Available! Download our document on arthritis myths below. https://t.co/2Kxpou4Fbz https://t.co/iPIqR92ME1
Dr. John Cush RheumNow ( View Tweet)
Dec 23, 2020
#ACR20 Mid Meeting Recap: Gout https://t.co/MhaYjotrmb https://t.co/R4dOrSlFl6
Dr. John Cush RheumNow ( View Tweet)
Dec 23, 2020
Cardiovascular Safety for Feboxustat with Dr. Nicola Dalbeth examines the cardiovascular safety in the FAST trial of Feboxustat at #ACR20. https://t.co/XCdtWpLKWR https://t.co/BLQdK6tq2s
Dr. John Cush RheumNow ( View Tweet)
Dec 21, 2020
Early view in ACR Open Access: Patient Perspectives on Gout and Gout Treatments: A Patient Panel Discussion That Informed the 2020 American College of Rheumatology Treatment Guideline https://t.co/QY6pofhamT

ACR_Journals ACR_Journals ( View Tweet)

Dec 18, 2020
Four Lifestyle Changes to Prevent Gout JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men. Read more below. https://t.co/6eYA75TjPx https://t.co/kLG9ANCxB9
Dr. John Cush RheumNow ( View Tweet)
Dec 15, 2020
Dr. Ken Saag -- RECIPE Study: MMF with Pegloticase Dr. Jack Cush interviews Dr. Ken Saag about the benefits of adding mycophenolate to your pegloticase regimen in refractory gout patients. #acr20 https://t.co/lpDuahgiVa https://t.co/nb8TqwKP5W
Dr. John Cush RheumNow ( View Tweet)
Dec 14, 2020

Four Lifestyle Changes to Prevent Gout

MedPage Today
Dec 14, 2020

JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men.



Over a 26-year period, about 77% (95% CI 56%-88%) of men likely could have avoided gout if they likewise avoid four major risk factors -- high BMI, poor diet high in salt,

Read Article
Important Gout cohort study of 44 654 US men followed x 26 yrs, shows that 77% of incident gout would have been prevented with thes 4 modifiable risk factors: 1) normal weight, 2) adhere to DASH diet, 3) no alcohol, & 4) no diuretics https://t.co/UsDAN8OykX https://t.co/ivBTb8Nyfw
Dr. John Cush RheumNow ( View Tweet)
Dec 14, 2020
What's New in Calcium Pyrophosphate Disease? NYU's Dr. Michael Pillinger discusses about Dr. Ann Rosenthal's state of the art talk on calcium pyrophosphate disease at #ACR20. https://t.co/UDxku4xK0C https://t.co/J661yvO06S
Dr. John Cush RheumNow ( View Tweet)
Dec 12, 2020
Febuxostat bad for the heart? Not so FAST: Dr. Jeffrey Curtis ( @RADoctor) #ACR20 https://t.co/8YFjGslJ7E

Dr. John Cush RheumNow ( View Tweet)

Dec 11, 2020
Comorbidities in Gout with Dr. Nicola Dalbeth https://t.co/RfXfk1MnWj https://t.co/X01lbf5fm7
Dr. John Cush RheumNow ( View Tweet)
Dec 08, 2020
Pipeline Therapies for Urate Lowering: Dr. Michael Pillinger #ACR20 https://t.co/M3ahjjZWK8 https://t.co/Ipc0nowK2t
Dr. John Cush RheumNow ( View Tweet)
Dec 03, 2020

Colchicine Approval Took a Huge Toll on CMS

Dec 03, 2020

Colchicine, the old gout drug often cited as a cheap anti-inflammatory, hasn't been such a good deal since FDA approval, a study in JAMA Internal Medicine showed.

Read Article
#BestACR20Tweets FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/EUXQqy3VuI
Dr. John Cush RheumNow ( View Tweet)
Dec 01, 2020
#BestACR20Tweets RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat

Dr. John Cush RheumNow ( View Tweet)

Dec 01, 2020
×